RT Journal Article
SR Electronic
T1 A Microdose PET Study of the Safety, Immunogenicity, Biodistribution, and Radiation Dosimetry of <sup>18</sup>F-FB-A20FMDV2 for Imaging the Integrin α<sub>v</sub>β<sub>6</sub>
JF Journal of Nuclear Medicine Technology
JO J. Nucl. Med. Technol.
FD Society of Nuclear Medicine
SP 136
OP 143
DO 10.2967/jnmt.117.203547
VO 46
IS 2
A1 Keat, Nicholas
A1 Kenny, Julia
A1 Chen, Keguan
A1 Onega, Mayca
A1 Garman, Nadia
A1 Slack, Robert J.
A1 Parker, Christine A.
A1 Lumbers, R. Thomas
A1 Hallett, Will
A1 Saleem, Azeem
A1 Passchier, Jan
A1 Lukey, Pauline T.
YR 2018
UL http://tech.snmjournals.org/content/46/2/136.abstract
AB The αvβ6 integrin is involved in the pathogenesis of cancer and fibrosis. A radiolabeled 20-amino-acid αvβ6-binding peptide, derived from the foot and mouth virus (NAVPNLRGDLQVLAQKVART [A20FMDV2]), has been developed to image αvβ6 levels preclinically. This study was designed to translate these findings into a clinical PET imaging protocol to measure the expression of αvβ6 in humans. Methods: Preclinical toxicology was undertaken, and a direct immunoassay was developed for 4-fluorobenzamide (FB)-A20FMDV2. Four healthy human subjects (2 male and 2 female) received a single microdose of 18F-FB-A20FMDV2 followed by a multibed PET scan of the whole body over more than 3 h. Results: There were no findings in the preclinical toxicology assessments, and no anti-A20FMDV2 antibodies were detected before or after dosing with the PET ligand. The mean and SD of the administered mass of 18F-FB-A20FMDV2 was 8.7 ± 4.4 μg (range, 2.7–13.0 μg). The mean administered activity was 124 ± 20 MBq (range, 98–145 MBq). There were no adverse or clinically detectable pharmacologic effects in any of the subjects. No significant changes in vital signs, laboratory study results, or electrocardiography results were observed. Uptake of radioactivity was observed in the thyroid, salivary glands, liver, stomach wall, spleen, kidneys, ureters, and bladder. Time–activity curves indicated that the highest activity was in the bladder content, followed by the kidneys, small intestine, stomach, liver, spleen, thyroid, and gallbladder. The largest component of the residence times was the voided urine, followed by muscle, bladder, and liver. Using the mean residence time over all subjects as input to OLINDA/EXM, the effective dose was determined to be 0.0217 mSv/MBq; using residence times from single subjects gave an SD of 0.0020 mSv/MBq from the mean. The critical organ was the urinary bladder, with an absorbed dose of 0.18 mGy/MBq. Conclusion: 18F-FB-A20FMDV2 successfully passed toxicology criteria, showed no adverse effects in this first-in-humans study, and has an effective dose that enables multiple scans in a single subject.